Rituximab to Treat Severe Hemophilia A

ClinicalTrials.gov ID: NCT00331006

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00331006. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Rituximab for the Treatment of Inhibitors in Congenital Hemophilia A (A TMH CTN Study)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Hemophilia A is a serious blood clotting disorder caused by a lack of factor VIII, a specialized protein needed for normal blood clotting to occur. Individuals with this disease may experience spontaneous bleeding, pain and swelling in their joints due to excess bleeding, and bruising. A common treatment for severe hemophilia A is to intravenously replace the deficient blood clotting factor; however, some individuals may develop antibodies to this replacement factor. This study will evaluate the effectiveness of rituximab at reducing the antibodies that develop in response to the replacement factor in individuals with severe hemophilia A.

Study identification

NCT ID: NCT00331006
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Carelon Research; Other
Enrollment: 23 participants

Conditions and interventions

Conditions

Hemophilia A

Interventions

Rituximab Drug

Drug

Eligibility (public fields only)

Age range: 18 Months and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 2006 (Type not available)
Primary completion: Nov 2010 (Actual)
Completion: Jan 2012 (Actual)
Last update posted: Jun 11, 2013

2006 – 2012

United States locations

U.S. sites: 13
U.S. states: 11
U.S. cities: 13

Facility	City	State	ZIP	Site status
Children's Hospital of Orange County	Orange	California	92868	—
Children's Healthcare of Atlanta	Atlanta	Georgia	30322	—
Rush University Medical Center	Chicago	Illinois	60612	—
Tulane University Health Sciences Center	New Orleans	Louisiana	70112	—
Children's Hospital Boston	Boston	Massachusetts	02115	—
UNC at Chapel Hill Hospital	Chapel Hill	North Carolina	27514	—
University Hospital of Cleveland	Cleveland	Ohio	44106	—
University of Oklahoma Health Sciences Center	Oklahoma City	Oklahoma	73104	—
Children's Hospital of Philadelphia	Philadelphia	Pennsylvania	19104	—
Hemophilia Center of Western Pennsylvania	Pittsburgh	Pennsylvania	15213	—
University of Texas Southwestern Medical Center	Dallas	Texas	75390	—
Cook Children's Medical Center	Fort Worth	Texas	76104	—
Comprehensive Center for Bleeding Disorders	Milwaukee	Wisconsin	53201	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00331006, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 11, 2013 · Synced Nov 11, 2026